


Ask a doctor about a prescription for MIDAZOLAM B. BRAUN 5 mg/ml SOLUTION FOR INJECTION/INFUSION
Package Leaflet: Information for the User
Midazolam B. Braun 5 mg/ml Solution for Injection and Infusion EFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Midazolam B. Braun is a short-acting medicine used to induce sedation (a very relaxed state of calmness, drowsiness or sleep) and to relieve anxiety and muscle tension. Its active substance, midazolam, belongs to a group of substances called benzodiazepines.
This medicine is used in adults:
This medicine is also used in adults and children:
Do not use Midazolam B. Braun:
Warnings and precautions
Consult your doctor or pharmacist before starting to use Midazolam B. Braun.
You will be closely monitored while receiving the medicine. Your doctor will also ensure that the necessary equipment and medicines are available for emergency treatment and resuscitation.
Your doctor will take special precautions and may adjust the dose with special attention if:
If you receive this medicine for a long period, you may:
Midazolam will cause memory loss that will start with administration. The duration will depend on the dose you receive. If you are discharged from the hospital or clinic after a surgical or diagnostic procedure, make sure someone accompanies you home.
Children
If your child is going to receive this medicine:
Other medicines and Midazolam B. Braun
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those obtained without a prescription and herbal products.
This is especially important because Midazolam B. Braun can affect the effect of other medicines. Similarly, other medicines can affect the effect of Midazolam B. Braun.
In particular, tell your doctor if you are taking any of the following medicines:
Using Midazolam B. Braun with alcohol
Do not drink alcoholic beverages if you are receiving midazolam, as alcohol will increase the effect of midazolam in an uncontrolled manner. This could cause serious adverse reactions in breathing, heart function and circulation.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
If you are pregnant, you will receive midazolam only if your doctor considers it absolutely necessary in the context of your treatment.
If you are breast-feeding, stop breast-feeding for 24 hours after administration of midazolam, as it may pass into breast milk.
Driving and using machines
Do not drive or use any tools or machines until you have fully recovered from midazolam. Your doctor will tell you when you can resume this activity.
This medicine may cause you to feel drowsy and affect your concentration and coordination. Make sure someone accompanies you home when you are discharged.
Midazolam B. Braun contains sodium
This medicine contains 2.19 mg of sodium (main component of table/cooking salt) in each 1 ml ampoule. This is equivalent to 0.11% of the maximum recommended daily intake of sodium for an adult.
This medicine contains 6.58 mg of sodium (main component of table/cooking salt) in each 3 ml ampoule. This is equivalent to 0.33% of the maximum recommended daily intake of sodium for an adult.
This medicine contains 21.94 mg of sodium (main component of table/cooking salt) in each 10 ml ampoule. This is equivalent to 1.01% of the maximum recommended daily intake of sodium for an adult.
This medicine will be administered to you by a doctor or nurse. It will be used in a place equipped to monitor you and to treat any adverse effects that may occur. This place may be a hospital or an outpatient surgery clinic. In particular, your breathing, heart function and circulation will be monitored.
It is not recommended to use this medicine in newborns or children under 6 months of age. However, in intensive care situations, it may be used in newborns and children under 6 months of age if the doctor considers it necessary.
Midazolam will be administered with a syringe (as an injection) into a vein (intravenously) or into a muscle (intramuscularly). It can also be administered diluted in a larger amount of liquid, through a cannula placed in a vein (by infusion). Rectal administration with a special applicator is also possible if injection or infusion is not feasible.
Posology:
Your doctor will determine the correct dose for you or your child, depending on the treatment you or your child will receive and depending on your or your child's condition.
If you use more Midazolam B. Braun than you should
This medicine will be administered to you by a doctor. If you accidentally receive too much midazolam, you may feel:
Treatment of overdose consists mainly of monitoring your vital functions (heart function, circulation and breathing). You will receive adequate support if necessary.
In cases of severe poisoning, you may receive a special antidote to counteract the effect of midazolam.
If you stop using Midazolam B. Braun
If you stop treatment suddenly after prolonged use, you may suffer from withdrawal symptoms such as:
Your doctor will gradually reduce the dose towards the end of treatment with midazolam to avoid these effects.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have been reported (frequency not known: cannot be estimated from the available data).
The following side effects may be serious. If you experience any of the following side effects, tell your doctor immediately, who will stop administering this medicine:
Life-threatening side effects are more likely to occur in adults over 60 years old and in those who already have breathing or heart problems, especially if the injection is given too quickly or with a high dose.
Other side effects:
Immune system disorders:
Behavioral effects:
Muscle disorders:
Mental and nervous system disorders:
Cardiovascular disorders:
Respiratory disorders:
Gastrointestinal disorders:
Skin disorders:
Administration site disorders:
General disorders:
Traumatic injuries, poisonings and complications of therapeutic procedures:
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Your doctor or pharmacist is responsible for storing this medicine. They are also responsible for disposing of unused midazolam correctly.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month shown.
Do not store above 25°C.
Chemical and physical stability have been demonstrated in use for 24 hours at room temperature and for 3 days at 5°C. From a microbiological point of view, the dilutions should be used immediately after preparation. If not used immediately, the in-use storage times and conditions are the responsibility of the user and normally should not exceed 24 hours between 2 and 8°C, unless the dilution method precludes any risk of microbial contamination.
Store the ampoules in the outer packaging to protect them from light.
Composition of Midazolam B. Braun
Each ml of Midazolam B. Braun 5 mg/ml contains 5 milligrams of midazolam.
Appearance of the Product and Packaging Contents
Midazolam B. Braun is a clear and colorless aqueous solution.
Midazolam B. Braun 5 mg/ml is presented in:
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Carl-Braun-Strasse 1
34212 Melsungen, Germany
Mailing Address:
34209 Melsungen, Germany
Phone: +495661713383
Manufacturer:
Ctra. de Terrassa, 121.
Rubi (Barcelona) 08191B.
Braun Melsungen AG
Carl-Braun-Strasse 1
34212 Melsungen, Germany
For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:
Carretera de Terrassa 121,
Rubí,
08191, Barcelona, Spain
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Belgium | Midazolam B. Braun 5 mg/ ml |
Cyprus | Midazolam B. Braun 5 mg/ ml |
Denmark | Midazolam B. Braun 5 mg/ ml |
Estonia | Midazolam B. Braun 5 mg/ ml |
France | Midazolam B. Braun 5 mg/ ml |
Germany | Midazolam B. Braun 5 mg/ ml |
Greece | Midazolam B. Braun 5 mg/ ml |
Italy | Midazolam B. Braun 5 mg/ ml |
Latvia | Midazolam B. Braun 5 mg/ ml |
Lithuania | Midazolam B. Braun 5 mg/ ml |
Luxembourg | Midazolam B. Braun 5 mg/ ml |
Malta | Midazolam B. Braun 5 mg/ ml |
Norway | Midazolam B. Braun 5 mg/ ml |
Poland | Midazolam B. Braun |
Slovenia | Midazolam B. Braun 5 mg/ ml solution for injection/infusion |
Spain | Midazolam B. Braun 5 mg/ ml |
Date of the Last Revision of this Leaflet:October 2023
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
----------------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Warnings
Paradoxical reactions
With midazolam, paradoxical reactions have been reported, such as restlessness, agitation, irritability, involuntary movements (including tonic-clonic convulsions and muscle tremors), hyperactivity, hostility, delirium, anger, aggression, anxiety, nightmares, hallucinations, psychosis, inappropriate behavior, and other adverse effects on behavior, paroxysmal excitement, and attacks. These reactions may occur with high doses and/or if the injection is administered rapidly. The highest incidence of such reactions has been described in children and the elderly. If these reactions occur, consideration should be given to discontinuing the administration of the medicinal product.
Sleep Apnea
Midazolam should be used with extreme caution in patients with sleep apnea syndrome and patients should be periodically monitored.
Handling
The medicinal product should be used immediately after opening.
Validity period after dilution according to the instructions:
Chemical and physical stability has been demonstrated for 24 hours at room temperature and for 3 days at 5°C.
From a microbiological point of view, dilutions should be used immediately after preparation. If not used immediately, the in-use storage times and conditions are the responsibility of the user and normally should not exceed 24 hours between 2 and 8°C, unless the dilution has been made in controlled and validated aseptic conditions.
The product is supplied in single-dose containers. The unused contents of opened containers should be discarded immediately.
Use only if the solution is clear and colorless and the container and its safety closure are not damaged.
Consult the summary of product characteristics or package leaflet for instructions for dilution, incompatibilities, and complete prescribing information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MIDAZOLAM B. BRAUN 5 mg/ml SOLUTION FOR INJECTION/INFUSION – subject to medical assessment and local rules.